LITMUS is a large consortium that reunites clinicians and scientists across Europe with the common goal of developing, validating, and qualifying better biomarkers for NAFLD. In this episode of EASL Studio, the following questions are addressed:

  • Why do we need more specific biomarkers?
  • Which populations should be included in trials and registries for the search of new biomarkers?
  • How do we take different patient demographics, co-morbidities and concomitant treatments, into consideration?
  • Are new sophisticated biomarkers necessary?


This EASL Studio has been sponsored by Intercept Pharmaceuticals Europe Limited. The sponsor have had no editorial control over the content featured.
Intercept’s subsidiaries and operations in Europe, Canada, and all other markets outside of the U.S. were acquired by Advanz Pharma on 1st July 2022. Intercept- branded videos, which are available on this site, all concern events which took place prior to 1st July 2022. For more information learn more here.


ℹ️ Please click here to access the podcast version of this EASL Studio episode.



Massimo Pinzani

Massimo Pinzani is Professor of Medicine at University College London (UCL), London, United Kingdom. He is a clinical and translational hepatologist, Sheila Sherlock Chair of Hepatology and Director of the UCL Institute for Liver and Digestive Health, Division of Medicine. He is also one of the pioneers in the research dedicated to cellular and molecular mechanisms of liver fibrosis and relative diagnostic and therapeutic approaches. His current research focus is regenerative medicine and on the development of extracellular matrix scaffold of liver, pancreas and small intestine for cell bioengineering and 3D disease modelling. He served as Educational Councillor and member of the governing board of the European Association for the Study of the Liver (EASL).


William Alazawi William Alazawi is Professor of Hepatology at Queen Mary University of London and a Consultant Hepatologist. Professor Alazawi looks after patients with a broad range of liver diseases, with particular interest in non-alcoholic fatty liver disease. He leads a thriving translational and clinical research group, funded by Medical Research Council, Wellcome and charities. 
Quentin Anstee Prof Quentin M. Anstee is the Chair of Experimental Hepatology and the Deputy-Dean of Research & Innovation in the Faculty of Medical Sciences, Newcastle University, UK. A practicing clinician, he is also an Honorary Consultant Hepatologist in the Liver Transplant Unit at Newcastle’s Freeman Hospital, where he leads one of the largest Non-Alcoholic Fatty Liver Disease (NAFLD) clinical services in the U.K. He coordinates two major international research consortia studying NAFLD pathogenesis and developing/validating accurate biomarkers to assist the diagnosis, risk-stratification and monitoring of patients with NAFLD: ‘EPoS’ Elucidating Pathways of Steatohepatitis and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis. He has established a pan-European NAFLD Registry and is an Associate Editor of the Journal of Hepatology.